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Abstract
Indication of Ventricular assistance is advanced cardiac failure with maximal 
medical and surgical treatment has been used. The ventricular assistance has two 
main purposes: first, to maintain circulation by discharging the ventricle (s) untill 
to recovery, or to ensure patient survival by replacing cardiac function permanently 
or transitionally for patients waiting for heart Transplantation. The encouraging 
results of the partial or total artificial heart and the miniaturization of these devices 
allow their use in permanent implantation for patients with heart failure that is not 
eligible for heart transplantation. In left mono-ventricular assistance, blood is taken 
from the apex of the left ventricle (LV) and reinjected in the ascending aorta. The 
classic surgical approach is a total median sternotomy. Other minimally invasive 
approaches for the implantation or explanation of left ventricular assist devices 
have been published and have shown encouraging results. These alternatives 
currently play an important role in certain indications and in patients with heavy 
medical history. Nevertheless, the complications of the ventricular assistance even 
by minimally invasive approaches might be serious and represent a turning point 
in the life of the patients. In this chapter, we describe the implantation technique of 
left ventricular assistance device (LVAD) and we discuss its advantages and disad-
vantages including possible complications.
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1. Introduction
End-stage heart failure has an increasing incidence and prevalence worldwide. 
In Germany, 1 to 2% of the population suffers from chronic heart failure, with 
approximately 80,000 new cases per year. Cardiac transplantation has been the 
therapy of choice for patients with drug-resistant heart failure, but the decreas-
ing number of donor organs leads to a significant prolongation of the waiting 
time for cardiac transplantation, resulting in an increased mortality of these 
patients [1, 2]. Indication of ventricular assistance device is for patients with 
advanced heart failure in whom maximum medical and surgical treatment has 
been exhausted. The purpose of ventricular assistance is twofold: first, to main-
tain circulation by discharging the ventricle (s) untill to recovery, and second, to 
ensure the survival of the patient by replacing the cardiac function, permanently 
or while waiting for a heart transplantation [3, 4].
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The encouraging results of the partial or total artificial heart and the miniatur-
ization of these devices make it possible to consider their use in permanent implan-
tation for patients with heart failure who are not eligible for heart transplantation.
In left mono-ventricular assistance, the blood is taken through a cannula placed 
at the apex of the left ventricule (LV) and re-injected to the patient by a vascular 
prosthesis anastomosed to the ascending aorta. The classic surgical approach is a 
total midline sternotomy. Alternative minimally invasive approaches for implanta-
tion or explantation of left ventricular assist devices have been published and have 
shown encouraging results [5]. These alternatives currently play an important role 
in certain precise indications and in the most complex patients. Nevertheless, the 
complications after the implantation of mechanical assistance, even by a minimally 
invasive route, are still serious and can be lethal.
The impact of heart failure on individuals and society in general continues to grow. 
Heart transplantation remains the gold standard for treating patients with end-stage 
heart failure. The development of artificial hearts, partial and total, was mainly inspired 
by the disproportion between the number of available grafts and the number of can-
didates for heart transplantation. The significant technological advances made since 
Kolff’s first work in 1957 allow these patients to return to their homes while awaiting 
the transplant. The encouraging results of the artificial heart and the miniaturization of 
these devices now make it possible to consider their use in permanent implantation for 
patients with heart failure who are not eligible for transplantation [6].
The objectives can be divided into two categories:
• Support and optimization of hemodynamic constants while waiting for the 
replacement of an irreversibly damaged heart (bridge-to-transplantation). 
This attitude improves pulmonary hypertension and prevents multiorgan 
failure [7].
• Definitive implantation of a mechanical heart because the patient has a 1-year 
mortality greater than 50% but is not a candidate for a heart transplantation 
(destination therapy); survival then depends on the technical reliability of the 
system and on intercurrent complications. It is currently 60–86% at 1 year, 
more than double that of maximum medical treatment [8–11].
Implanted early enough in the course of the disease, ventricular assistance helps 
restore renal and hepatic functions, reduce pulmonary hypertension, mobilize 
excess interstitial fluid and prevent the onset of a multiorgan failure. Criteria for 
LVAD implantation are the persistence of the following settings despite maximum 
medical treatment:
• Cardiac index <2.0 L/ min/m2
• Mean arterial pressure (MAP) <60 mmHg, systolic arterial 
pressure < 80 mmHg.
• Central venous pressure CVP and/or mean arterial pressure > 20 mmHg,
• systemic arterial resistance >2,000 dynes/s/cm-5.
• Lesft ventricular ejection function <0.25
• Venous saturation of oxygen <55%
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• diuresis <20 mL/hour.
• Persistent metabolic acidosis.
Assistance is contraindicated in active systemic infection, irreversible neu-
rological impairment, and end-stage renal or hepatic failure. Severe peripheral 
vascular disease and haematological disorders are relative contraindications [12]. 
The aortic valve must be continent, otherwise the flow of assistance will flow back 
into the LV and dilate it. Severe pulmonary hypertension or right heart failure are 
a contraindication to left monoventricular assistance; in this case, biventricular 
assistance must be performed (20% of cases).
Of course, ventricular assistance is an expensive therapy. Long-term implanted 
pumps (destination therapy) represent an expense of around € 220,000 [13]. 
Ventricular assist systems can be classified in three generations [3, 14]:
• 1st generation: extracorporeal pulsatile devices, often pneumatic, driven by an 
external console (Thoratec PVAD ™, Abiomed BVS 5000 ™); they are bulky 
and contain many moving parts, including valves.
• 2nd generation: implantable pulsatile systems, most often electric (HeartMate 
XVE ™, LionHeart ™, Thoratec IVAD ™).
• 3rd generation: implantable axial flow systems, designed for long periods 
(HeartMate II ™, Jarvik 2000 ™, BerlinHeart ™); the only moving part is the 
rotor, valves are unnecessary; the latest models operate by magnetic levitation 
which eliminates the axes of the rotor, sources of wear.
HEARTMATE LVAD device is a mechanical, continuous flow, electrical, intra-
corporeal, monoventricular left circulatory device. This system is indicated when 
the patient’s body surface area is ≥1.2 m2 in the following situations:
• Indication in an acute situation: acute mono or biventricular failure in patients 
with heart failure, not controlled by optimal treatment, in the absence of 
a conventional therapeutic alternative (drug and / or intervention and/or 
surgery).
• Elective indication: advanced chronic heart failure with mono or biventricular 
failure, when life is threatened despite optimal treatment, and at the end of a 
multidisciplinary consultation.
The contraindications to HEARTMATE mechanical device are:
• severe pulmonary dysfunction and fixed pulmonary arterial hypertension.
• Severe hepatic insufficiency (cirrhosis, portal hypertension, …).
• Major disorders of blood crass and uncontrolled bleeding.
• Uncontrolled systemic septic and inflammatory syndrome.
• Documented irreversible central nervous system damage, recent stroke and 
cachexia.
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• Systemic diseases with involvement of several organs.
• Psychiatric disorders jeopardizing adherence to treatment and lack of 
cooperation.
• A condition with a bad prognosis when life expectancy is less than 2 years.
• An untreated septal rupture.
• A body surface area < 1.2 m2.
“HeartMate” is one of the continuous flow systems which are driven by an axial 
turbine (HeartMate ™ II, BerlinHeart ™, Jarvik 2000 ™, DeBakey MicroMed ™) or 
a centrifugal pump (HeartMate ™ III). They are implanted by sternotomy or thora-
cotomy. The blood is taken from the apex of the LV and returned to the ascending or 
descending aorta through a tubular prosthesis. The assured flow rate is 3 to 10 L/min. 
These simpler and quieter continuous flow systems are less prone to embolism and 
infections than pulsatile systems [14, 15]. In addition, they let the heart continue to 
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Their size is small, and they can be implanted in short patients. The arterial 
curve is practically flat, the systolic and diastolic blood pressure are the same as 
the Mean arteriel pressure. The functionality of the LV results in hooks added to 
this curve; these are all the more important as the LV performs better or the pump 
output decreases.
The smaller design of the pump and its intrapericardial location has allowed 
the development of less invasive alternatives and implantation techniques. The 
technique of left ventricular assistance by minimally invasive approach has been 
described in several publications [5, 16–19]. It consists of an upper J-shaped 
mini-sternotomy or an anterior thoracotomy in the 2nd right intercostal space for 
access to the ascending aorta (site of anastomosis of the ejection voice) as well as 
to the right atrium (if atriocaval cannulation) and a left subcostal approach or a 
left anterolateral thoracotomy of 8 to 10 Cm for access to the apex of the heart and 
implantation of the device (Figure 1 and 2).
According to Anson et al. [18], the use of small incisions allows exposure of the 
exact areas required for cannulation without the need for cardiac manipulation 
which is often poorly tolerated in these severe patients, and therefore implantation 
without cardiopulmonary bypass (CBP) becomes possible. In the study of Bantayehu 
Sileshi et al. [17] including 51 HeartWare implantations for patients waiting for heart 
transplantation, eighteen of them were with minimally invasive approach without 
CPB. The choice of the surgical technique was made by a multidisciplinary commit-
tee, taking into consideration the contraindications, in particular the respiratory one, 
for thoracotomy. Univariate analysis revealed a statistically significant reduction in 
the duration of treatment with inotropic drugs (p = 0.04), and reduced intraoperative 
Figure 2. 
Minimally invasive LVAD implantation approach.
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blood transfusion (p = 0.08) in minimally invasive implantations. Conversly, there 
was no difference regarding the duration of intensive care stay (p = 0.5), the total 
intra-hospital saty (p = 0.76) and the total time of mechanical ventilation (p = 0.32). 
There were four in-hospital deaths and three stroke complications all were operated 
on by sternotomy under CBP. Authors showd also an increasing risk of infection, 
bleeding and redo-sternotomy complications at the time of heart transplantation [20].
Less invasive surgical approaches have been developed with the hope of reducing 
CPB time and operative trauma, minimizing perioperative blood loss, protecting 
cardiac structures from multiple re-entries, and preserving the heart geometry [21].
Haberl and al. recently described their clinical experience in minimally invasive 
implantation for HeartWare and HeartMate II [22]. Of the 27 patients in their study, 
5 (19%) were performed without CPB. They had a reported in-hospital mortality 
of 14.8%, and an average hospital stay of 30 days. They concluded that minimally 
invasive LVAD implantation is feasible and safe. Moreover, Anelechi C [5] thinks 
that this technique is inadequate for patients who have previously had cardiac 
surgery without giving any arguments.
Minimally invasive approach was also recommended for the device remove 
or changing [23–27]. For example, the team of Igor D. Gregoric [23] showed the 
superiority of the subcostal route alone to change HeartMate XVE by HeratMate 
II compared to sternotomy with left subcostal approach in terms of transfusion, 
operative duration and postoperative stay. The same results were found in the study 
of John m. Stulak and his colleagues [26].
2. Complications
The complications related to the different assistance systems are  
numerous [11, 28, 29]:
• Infections in 32 to 45% of cases.
• Bleeding in 27% of cases.
• Arrhythmias in24% of cases.
• Thromboembolism and stroke (10–39% depending on the device type)
• Renal failure in 20% of cases.
• Systemic inflammation and lack of cellular immunity.
• Hemolysis: depending on the pump models.
infectious complications are the most serious with 41% of deaths linked to 
sepsis [30]. Continuous-flow turbine systems have a clearly lower complication rate 
(infections, thromboses, mechanical problems) than pulsatile systems [31].
There are basically three disadvantages of continuous flow systems:
• malfunction causes the equivalent of acute aortic insufficiency because there is 
no valve in the system.
• As they generate negative pressure in the LV, the ventricle can collapse with a sud-
den drop in preload and a risk of air embolism by aspiration of air at the sutures;
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• The continuous flow causes stasis in the aortic valve if it no longer opens; this 
can give rise to thrombi, with the risk of systemic embolization.
Thrombosis of the ventricular assist device (VAD) is associated with significant 
morbidity and mortality, usually requiring device replacement. Since 2011, there 
has been a sharp increase in the incidence of VAD thrombosis, from 2.2% before 
2011 to 8.4% in 2013 [32]. The exact reason for this increase is unknown and numer-
ous studies aim to identify it [33]. Diagnostic markers, including increased plasma 
lactate dehydrogenase (LDH), free plasma hemoglobin, or abnormal responses to 
programmed increases in pump speed (ramp test) [34] should allow early and more 
accurate diagnosis. [35].
The formation of thrombi in the aortic root in patients implanted with HeartMate 
II has been previously reported in the literature [36, 37]. The flow in the root of the 
aorta in patients with continuous flow LVAD has been shown experimentally to be 
relatively stagnant, especially when the aortic valve does not open [38] and such 
stasis often involves the non-coronary sinus and can be an important risk factor for 
thrombosis. Sachin Shah and colleagues [39] report a case of occlusion of the left 
common coronary trunk by aortic root thrombus in a patient with HeartMate II.
The optimal strategy for the prevention of this complication is not yet well 
defined; however, special attention to anticoagulation and antiplatelet therapy in 
the postoperative period, as well as adjusting the pump speed to allow intermittent 
opening of the aortic valve may be important considerations. For those who develop 
an aortic root thrombus, but remain asymptomatic, intensification of anticoagula-
tion and antiplatelet therapy alone may sometimes be sufficient [39].
3. Conclusion
In conclusion, with the limited number of organ donors, long-term ventricular 
support systems are slowly becoming an alternative to heart transplantation. 
Significant technical advances have allowed the development of small, space-saving 
ventricular assist devices with fewer complications.
Minimally invasive alternative approaches for implantation or explantation of left 
ventricular assist devices have become valid and reproducible. Nevertheless, com-
plications, in particular thromboembolic still serious. Only multidisciplinary work 
associating surgeon, cardiologist and anesthetist with perfect knowledge of the man-
agement of these patients and these machines can prevent complications abd death.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
8
Cardiac Diseases - Novel Aspects of Cardiac Risk, Cardiorenal Pathology and Cardiac Interventions
[1] Haeck ML, Beeres SL, Höke U,  
Palmen M, Couperus LE, Delgado V,  
Logeman EA, Maas JJ, Klautz RJ, 
Schalij MJ, Verwey HF. Left ventricular 
assist device for end-stage heart failure: 
results of the first LVAD destination 
program in the Netherlands. Neth 
Heart J. 2015 Feb;23(2):102-108. doi: 
10.1007/s12471-014-0602-4.
[2] Christiansen S, Klocke A, 
Autschbach R. Past, present, and future 
of long-term mechanical cardiac 
support in adults. J Card Surg. 
2008 Nov-Dec;23(6):664-676. doi: 
10.1111/j.1540-8191.2008.00696.x.
[3] TERRACCIANO CM, MILLER LW, 
YACOUB MH. Contemporary use of 
ventricular assist devices. Annu Rev 
Med 2010; 61:255-270.
[4] VEGAS A. Assisting the failing heart. 
Anesthesiology Clin 2008; 26:539-564.
[5] Anelechi C Anyanwu. 
Nonsternotomy Approaches to Left 
Ventricular Assist Device placement: 
Combined Left Subcostal–Right 
Minithoracotomy Technique. 
Operative Techniques in Thoracic and 
Cardiovascular Surgery. Nov 2014; vol 
19(3): 254-275.
[6] E. Flecher, T. Joudinaud, J.-M. 
Grinda. Histoire de l'assistance 
circulatoire mécanique et du cœur 
artificiel. Annales de chirurgie oct 2006; 
Vol 131(8): 473-478.
[7] CHRISTIANSEN S, KLOCKE A, 
AUTSCHBACH R. Past, present, and 
future of long term mechanical cardiac 
support in adults. J Card Surg 2008; 
23:664-676.
[8] BADIWALA MV, RAO V. Left 
ventricular device as destination 
therapy: are we there yet ? Curr Opin 
Cardiol 2009; 24:184-189.
[9] BIRKS EJ, GEORGE RS, HEDGER 
M, et al. Reversal of heart failure with 
a continuous-flow left ventricular 
assistance device and pharmacological 
therapy. Circulation 2011; 123:381-390.
[10] LONG JW, KFOURY AG, 
SLAUGHTER MS, et al. Long 
term destination therapy with the 
HeartMate XVE left ventricular assist 
device: improved outcomes since the 
REMATCH study. Congest Heart Fail 
2005; 11:133-138.
[11] ROSE EA, GELIJNS AC, 
MOSKOWITZ AJ, et al. REMATCH 
study group. Long-term mechanical 
left ventricular assistance for end-
stage heart failure. N Engl J Med 2001; 
345:1435-1443.
[12] EL-MAGHARBEL I. Ventricular 
assist devices and anesthesia. Semin 
Cardiothor Vasc Anesth 2005; 
9:241-249.
[13] MOHACSI P, STALDER M, 
MARTINELLI M, et al. Transplantation 
cardiaque et assistance circulatoire 
mécanique. Situation actuelle et 
perspectives. 2ème partie. Forum Med 
Suisse 2011; 11:98-102.
[14] THUNBERG CA, GAITAN 
BD, ARABIA FA, et al. Ventricular 
assist devices today and tomorrow. 
J Cardiothorac Vasc Anesth 2010: 
24:656-680.
[15] FRAZIER OH, GEMMATO 
C, MYERS TJ, et al. Initial clinical 
experience with the HeartMate II axial-
flow left ventricular assist device. Tex 
Heart Inst J 2007; 34:275-281.
[16] Chad EW, Julien SB, Jason K, et 
al. Minimally invasive thoracic left 
ventricular assist device implantation: 
Case series demonstrating an integrate 
multidisciplinary strategy. Journal of 
References
9
Complications of Minimally Invasive Left Ventricular Assistance Device Implantation
DOI: http://dx.doi.org/10.5772/intechopen.95638
cardiothoracic and vascular anesthesia, 
avril 2015 vol 29(2):271-274.
[17] Bantayehu S, Nicholas AH, Mary ED 
et al.In-hospital outcomes of minimally 
invasive off-pump left thoracotomy 
approach using a centrifugal 
continuous-flow left ventricular 
assist device. J Heart lung Transplant 
2015;34:107-112.
[18] Anson C, Yoan L, Annemarie K, 
et al. Off-pump implantation of the 
HeratWare HVAD left ventricular assist 
device through minimally invasive 
incisions. Ann Thorac Surg 2011; 
91:1294-1296.
[19] Schmitto JD, Molitoris U, 
Haverich A, et al. Implantation of a 
centrifugal pump as a left ventricular 
assist device through a novel, minimized 
approach: upper hemisternotomy 
combined with antero-lateral 
thoracotomy. J Thorac Cardiovasc Surg 
2012;143:511-513.
[20] Unsworth B, Casula RP, 
Kyriacou AA, et al. The right ventricular 
annular velocity reduction caused by 
coronary artery bypass graft surgery 
occurs at the moment of pericardial 
incision. Am Heart J 2010;159:314-322.
[21] Schmitto JD, Mokashi SA, Cohn LH. 
Minimally-invasive valve surgery. J Am 
Coll Cardiol 2010;56:455-462.
[22] Haberl T, Riebandt J, Mahr S, 
Laufer G, Rajek A, Schima H, Zimpfer D. 
Viennese approach to minimize the 
invasiveness of ventricular assist device 
implantation†. Eur J Cardiothorac Surg. 
2014 Dec;46(6):991-996; discussion 
996. doi: 10.1093/ejcts/ezu051.
[23] Igor D, Brian A, Leon J, et al. 
Clinical Experience With Sternotomy 
Versus Subcostal Approach for 
Exchange of the HeartMate XVE to the 
HeartMate II Ventricular Assist Device. 
Ann Thorac Surg 2008;85:1646-1650.
[24] Sajjad M, Butt T, Oezalp F, et al. An 
alternative approach to explantation 
and exchange of the HeartWare left 
ventricular assist device European 
Journal of Cardio-Thoracic Surgery 43 
(2013) :1247-1250.
[25] Diana GS, Prashant NM, 
Bartlomiej Z, et al. Minimally invasive 
access for off-pump HeartWare left 
ventricular assist device explantation. 
Interactive cardiovascular and thoracic 
surgery 17 (2013):581-582.
[26] John MS, Jennifer C, Jonathon WH, 
et al. Device exchange after primary left 
ventricular assist device implantation: 
indications and outcomes. Ann Thorac 
Surg 2013;95:1262-1268.
[27] Rojas SV, Avsar M, Khalpey Z, et 
al. Minimally invasive pff_pump left 
ventricular assist device exchange: 
anterolateral thoracotomy. Artif Organs 
2014;38(7):539-542.
[28] DENG MC, EDWARDS LB, 
HERRTZ MI, et al. Mechanical 
circulatory support data base of the 
international society for heart and lung 
transplantation: second annual report 
2004. J Heart Lung Transplant 2004; 
23:1027-1034.
[29] STONE ME. Current status of 
mechanical circulatory assistance. 
Semin Cardiothor Vasc Anesth 2007; 
11:185-204.
[30] CHRISTIANSEN S, KLOCKE A, 
AUTSCHBACH R. Past, present, and 
future of long term mechanical cardiac 
support in adults. J Card Surg 2008; 
23:664-676.
[31] MITTER N, SHEINBERG R. Update 
on ventricular assist devices. Curr Opin 
Anaesthesiol 2009; 23:57-66.
[32] Starling RC, Moazami N, 
Silvestry SC, et al. Unexpected abrupt 
increase in left ventricular assist device 
Cardiac Diseases - Novel Aspects of Cardiac Risk, Cardiorenal Pathology and Cardiac Interventions
10
thrombosis. N Engl J Med, 2014; 
370:33-40.
[33] Edo Y. Birati MD, J. Eduardo 
Rame MD. Diagnosis and Management 
of LVAD Thrombosis. Curr Treat 
Options Cardio Med, February  
2015, 17:2.
[34] Uriel N, Morrison KA, 
Garan AR, et al. Development of a novel 
echocardiography ramp test for speed 
optimization and diagnosis of device 
thrombosis in continuous-flow left 
ventricular assist devices: the Columbia 
Ramp Study. J Am Coll Cardiol, 2012; 
60:1764-1765.
[35] Uriel N, Han J, Morrison KA, et 
al. Device thrombosis in HeartMate II 
continuous-flow left ventricular assist 
devices: a multifactorial phenomenon. J 
Heart Lung Transplant, 2014;33: 51-59.
[36] Freed BH, Jeevanandam V, Jolly N. 
Aortic root and valve thrombosis after 
implantation of a left ventricular assist 
device.J Invasive Cardiol, 2011; 23:63-65.
[37] Demirozu Z, Frazier O. Aortic 
valve noncoronary cusp thrombosis 
after implantation of a nonpulsatile, 
continuous-flow pump. Tex Heart Inst J, 
2012, 39 (5):618-620.
[38] Kar B, Delgado R, Frazier O, et al. 
The effect of LVAD aortic outflow-graft 
placement on hemodynamics and flow. 
Implantation technique and computer 
flow modeling.Tex Heart Inst J, 2005;32: 
294-298.
[39] Sachin S, Mehra M, Couper G, 
Desa A. Continuous flow left ventricular 
assist device related aortic root 
thrombosis complicated by left main 
coronary artery occlusion. The Journal 
of Heart and Lung Transplantation, 
2014; 33 (1):119-120.
